+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Embolotherapy Market Research Report: By Product, Procedure, Indication, End-User - Global Industry Analysis and Demand Forecast to 2030

  • ID: 4912387
  • Report
  • September 2021
  • Region: Global
  • 370 Pages
  • Prescient & Strategic Intelligence Private Limited

FEATURED COMPANIES

  • Abbott Laboratories
  • Acandis GmbH
  • BALT EXTRUSION SAS
  • Guerbet
  • Johnson & Johnson
  • Kaneka Corporation
The global embolotherapy market value, which was $3,082.9 million in 2020, will likely reach $6,447.1 million in 2030, at a 7.7% CAGR between 2020 and 2030, according to the market research report.



The key factors driving the demand for embolotherapy procedures are:


  • Growing Patient Pool: The number of patients suffering from hepatic cell carcinoma (HCC), varicose veins, renal cell carcinoma (RCC), and aneurysms is rising, thereby leading to an increasing mortality rate. For instance, the American Cancer Society has put the expected number of liver cancer cases to be diagnosed in the U.S. in 2021 at 42,230.
  • Rising Prevalence of Chronic Diseases: Another key driving factor for the embolotherapy market is the increasing prevalence of cancers and other chronic and lifestyle-associated diseases. According to the World Health Organization (WHO), cancer leads to 9.6 million deaths each year. Embolotherapy is rapidly becoming a preferred treatment for cancer as it cuts the tumor from the blood supply, essentially starving it of nutrients.

The COVID-19 pandemic has negatively affected the embolotherapy market by reducing both the supply and demand for the associated products. During the lockdowns, factories producing non-essential commodities were shut down and the supply chains were also disrupted. On the demand side, most surgery departments were closed as the focus shifted entirely to COVID care. This led to a drastic decrease in the number of embolotherapy procedures, which resulted in an extremely low demand for the associated products.

The embolic agents bifurcation will witness the faster growth within the product segment of the embolotherapy market in the years to come. The rising volume of interventional radiology procedures is driving the demand for a variety of embolic agents. Moreover, numerous technological advancements have been brought about in these products, such as radioactive yttrium-90 (Y-90) microspheres, drug-eluting microspheres, and calibrated microspheres for bland embolization.

In the coming years, the transcatheter arterial embolization (TAE) category will hold the largest share in the embolotherapy market, based on procedure. The rising demand for minimally invasive surgeries by the elderly and the fact that TAE is better tolerated by and effective in patients with a ruptured HCC are propelling the preference for TAE.

In the near future, the highest embolotherapy market CAGR, of 8.0%, under segmentation by end user, is projected to be witnessed by the hospitals & clinics category. Compared to ambulatory surgery centers and other facilities, hospitals and clinics witness a higher patient footfall as they boast cutting-edge equipment and experienced professionals.

North America is the largest embolotherapy market on account of the rising incidence of diseases that require such procedures. Moreover, the advanced healthcare sector of the region is complemented by the development of improved embolotherapy products by medical device and pharma companies.

Key players in the global embolotherapy market are Stryker Corporation, Sirtex Medical Limited, Terumo Corporation, Merit Medical Systems Inc., Medtronic Plc, Meril Life Sciences Pvt. Ltd., Kaneka Corporation, Boston Scientific Corporation, Johnson & Johnson, BALT EXTRUSION SAS, Abbott Laboratories, and Guerbet.
Frequently Asked Questions about the Embolotherapy Market

What is the estimated value of the Embolotherapy Market?

The Embolotherapy Market was estimated to be valued at $3082.9 Million in 2020.

What is the growth rate of the Embolotherapy Market?

The growth rate of the Embolotherapy Market is 7.7%, with an estimated value of $6447.1 Million by 2030.

What is the forecasted size of the Embolotherapy Market?

The Embolotherapy Market is estimated to be worth $6447.1 Million by 2030.

Who are the key companies in the Embolotherapy Market?

Key companies in the Embolotherapy Market include Stryker Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Meril Life Sciences Pvt. Ltd., Acandis GmbH, Terumo Corporation, Medtronic plc, Kaneka Corporation and Boston Scientific Corporation.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Acandis GmbH
  • BALT EXTRUSION SAS
  • Guerbet
  • Johnson & Johnson
  • Kaneka Corporation

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product
1.5.2 Market Segmentation by Procedure
1.5.3 Market Segmentation by Indication
1.5.4 Market Segmentation by End User
1.5.5 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 Publisher Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Embolic agents
4.1.1.1.1 Microspheres
4.1.1.1.2 Embolic coils
4.1.1.1.3 Liquid embolic agents
4.1.1.1.4 Embolic plug systems
4.1.1.1.5 Detachable balloons
4.1.1.2 Support devices
4.1.1.2.1 Microcatheters
4.1.1.2.2 Guidewires
4.1.2 By Procedure
4.1.2.1 TAE
4.1.2.2 TARE/SIRT
4.1.2.3 TACE
4.1.3 By Indication
4.1.3.1 Cancer
4.1.3.1.1 Kidney
4.1.3.1.2 Liver
4.1.3.1.3 Others
4.1.3.2 Peripheral vascular diseases
4.1.3.3 Neurological diseases
4.1.3.3.1 Cerebral aneurysm
4.1.3.3.2 Arteriovenous malformations & fistulas
4.1.3.4 Urological and nephrological disorders
4.1.3.5 Gastrointestinal disorders
4.1.4 By End User
4.1.4.1 Hospitals & clinics
4.1.4.2 ASCs
4.1.4.3 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of product approvals and launches
4.2.1.2 Increasing number of acquisitions
4.2.2 Drivers
4.2.2.1 Growing patient pool
4.2.2.2 Increasing prevalence of chronic and lifestyle-associated diseases
4.2.2.3 Growing medical tourism sector
4.2.2.4 Rising healthcare expenditure and improving healthcare infrastructure
4.2.2.5 Growing preference for MISs
4.2.2.6 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Risks and challenges associated with embolization
4.2.3.2 Product recalls
4.2.3.3 Dearth of skilled radiologists
4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Growing applications of liquid embolic agents
4.2.4.2 Untapped market in developing economies
4.3 Porter’s Five Forces Analysis
4.4 Regulatory Framework Analysis
4.4.1 U.S.
4.4.2 Europe
4.4.3 APAC
4.4.4 LATAM
4.4.5 MEA
Chapter 5. Global Market Size and Forecast
5.1 Global Market Size and Forecast
5.2 By Product
5.2.1 Embolic Agents Market, by Type
5.2.2 Embolotherapy Support Devices Market, by Type
5.3 By Procedure
5.4 By Indication
5.4.1 Embolotherapy Market for Cancer, by Type
5.4.2 Embolotherapy Market for Neurological Diseases, by Type
5.5 By End User
5.6 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Product
6.1.1 Embolic Agents Market, by Type
6.1.2 Embolotherapy Support Devices Market, by Type
6.2 By Procedure
6.3 By Indication
6.3.1 Embolotherapy Market for Cancer, by Type
6.3.2 Embolotherapy Market for Neurological Diseases, by Type
6.4 By End User
6.5 By Country
6.5.1 U.S. Market Size and Forecast
6.5.1.1 By product
6.5.1.1.1 Embolic agents market, by type
6.5.1.1.2 Embolotherapy support devices market, by type
6.5.1.2 By procedure
6.5.1.3 By indication
6.5.1.3.1 Embolotherapy market for cancer, by type
6.5.1.3.2 Embolotherapy market for neurological diseases, by type
6.5.1.4 By end user
6.5.2 Canada Market Size and Forecast
6.5.2.1 By product
6.5.2.1.1 Embolic agents market, by type
6.5.2.1.2 Embolotherapy support devices market, by type
6.5.2.2 By procedure
6.5.2.3 By indication
6.5.2.3.1 Embolotherapy market for cancer, by type
6.5.2.3.2 Embolotherapy market for neurological diseases, by type
6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
7.2 By Procedure
7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
7.4 By End User
7.5 By Country
7.5.1 Germany Market Size and Forecast
7.5.1.1 By product
7.5.1.1.1 Embolic agents market, by type
7.5.1.1.2 Embolotherapy support devices market, by type
7.5.1.2 By procedure
7.5.1.3 By indication
7.5.1.3.1 Embolotherapy market for cancer, by type
7.5.1.3.2 Embolotherapy market for neurological diseases, by type
7.5.1.4 By end user
7.5.2 France Market Size and Forecast
7.5.2.1 By product
7.5.2.1.1 Embolic agents market, by type
7.5.2.1.2 Embolotherapy support devices market, by type
7.5.2.2 By procedure
7.5.2.3 By indication
7.5.2.3.1 Embolotherapy market for cancer, by type
7.5.2.3.2 Embolotherapy market for neurological diseases, by type
7.5.2.4 By end user
7.5.3 U.K. Market Size and Forecast
7.5.3.1 By product
7.5.3.1.1 Embolic agents market, by type
7.5.3.1.2 Embolotherapy support devices market, by type
7.5.3.2 By procedure
7.5.3.3 By indication
7.5.3.3.1 Embolotherapy market for cancer, by type
7.5.3.3.2 Embolotherapy market for neurological diseases, by type
7.5.3.4 By end user
7.5.4 Italy Market Size and Forecast
7.5.4.1 By product
7.5.4.1.1 Embolic agents market, by type
7.5.4.1.2 Embolotherapy support devices market, by type
7.5.4.2 By procedure
7.5.4.3 By indication
7.5.4.3.1 Embolotherapy market for cancer, by type
7.5.4.3.2 Embolotherapy market for neurological diseases, by type
7.5.4.4 By end user
7.5.5 Spain Market Size and Forecast
7.5.5.1 By product
7.5.5.1.1 Embolic agents market, by type
7.5.5.1.2 Embolotherapy support devices market, by type
7.5.5.2 By procedure
7.5.5.3 By indication
7.5.5.3.1 Embolotherapy market for cancer, by type
7.5.5.3.2 Embolotherapy market for neurological diseases, by type
7.5.5.4 By end user
Chapter 8. APAC Market Size and Forecast
8.1 By Product
8.1.1 Embolic Agents Market, by Type
8.1.2 Embolotherapy Support Devices Market, by Type
8.2 By Procedure
8.3 By Indication
8.3.1 Embolotherapy Market for Cancer, by Type
8.3.2 Embolotherapy Market for Neurological Diseases, by Type
8.4 By End User
8.5 By Country
8.5.1 China Market Size and Forecast
8.5.1.1 By product
8.5.1.1.1 Embolic agents market, by type
8.5.1.1.2 Embolotherapy support devices market, by type
8.5.1.2 By procedure
8.5.1.3 By indication
8.5.1.3.1 Embolotherapy market for cancer, by type
8.5.1.3.2 Embolotherapy market for neurological diseases, by type
8.5.1.4 By end user
8.5.2 Japan Market Size and Forecast
8.5.2.1 By product
8.5.2.1.1 Embolic agents market, by type
8.5.2.1.2 Embolotherapy support devices market, by type
8.5.2.2 By procedure
8.5.2.3 By indication
8.5.2.3.1 Embolotherapy market for cancer, by type
8.5.2.3.2 Embolotherapy market for neurological diseases, by type
8.5.2.4 By end user
8.5.3 India Market Size and Forecast
8.5.3.1 By product
8.5.3.1.1 Embolic agents market, by type
8.5.3.1.2 Embolotherapy support devices market, by type
8.5.3.2 By procedure
8.5.3.3 By indication
8.5.3.3.1 Embolotherapy market for cancer, by type
8.5.3.3.2 Embolotherapy market for neurological diseases, by type
8.5.3.4 By end user
8.5.4 South Korea Market Size and Forecast
8.5.4.1 By product
8.5.4.1.1 Embolic agents market, by type
8.5.4.1.2 Embolotherapy support devices market, by type
8.5.4.2 By procedure
8.5.4.3 By indication
8.5.4.3.1 Embolotherapy market for cancer, by type
8.5.4.3.2 Embolotherapy market for neurological diseases, by type
8.5.4.4 By end user
8.5.5 Singapore Market Size and Forecast
8.5.5.1 By product
8.5.5.1.1 Embolic agents market, by type
8.5.5.1.2 Embolotherapy support devices market, by type
8.5.5.2 By procedure
8.5.5.3 By indication
8.5.5.3.1 Embolotherapy market for cancer, by type
8.5.5.3.2 Embolotherapy market for neurological diseases, by type
8.5.5.4 By end user
Chapter 9. LATAM Market Size and Forecast
9.1 By Product
9.1.1 Embolic Agents Market, by Type
9.1.2 Embolotherapy Support Devices Market, by Type
9.2 By Procedure
9.3 By Indication
9.3.1 Embolotherapy Market for Cancer, by Type
9.3.2 Embolotherapy Market for Neurological Diseases, by Type
9.4 By End User
9.5 By Country
9.5.1 Brazil Market Size and Forecast
9.5.1.1 By product
9.5.1.1.1 Embolic agents market, by type
9.5.1.1.2 Embolotherapy support devices market, by type
9.5.1.2 By procedure
9.5.1.3 By indication
9.5.1.3.1 Embolotherapy market for cancer, by type
9.5.1.3.2 Embolotherapy market for neurological diseases, by type
9.5.1.4 By end user
9.5.2 Mexico Market Size and Forecast
9.5.2.1 By product
9.5.2.1.1 Embolic agents market, by type
9.5.2.1.2 Embolotherapy support devices market, by type
9.5.2.2 By procedure
9.5.2.3 By indication
9.5.2.3.1 Embolotherapy market for cancer, by type
9.5.2.3.2 Embolotherapy market for neurological diseases, by type
9.5.2.4 By end user
Chapter 10. MEA Market Size and Forecast
10.1 By Product
10.1.1 Embolic Agents Market, by Type
10.1.2 Embolotherapy Support Devices Market, by Type
10.2 By Procedure
10.3 By Indication
10.3.1 Embolotherapy Market for Cancer, by Type
10.3.2 Embolotherapy Market for Neurological Diseases, by Type
10.4 By End User
10.5 By Country
10.5.1 Saudi Arabia Market Size and Forecast
10.5.1.1 By product
10.5.1.1.1 Embolic agents market, by type
10.5.1.1.2 Embolotherapy support devices market, by type
10.5.1.2 By procedure
10.5.1.3 By indication
10.5.1.3.1 Embolotherapy market for cancer, by type
10.5.1.3.2 Embolotherapy market for neurological diseases, by type
10.5.1.4 By end user
10.5.2 South Africa Market Size and Forecast
10.5.2.1 By product
10.5.2.1.1 Embolic agents market, by type
10.5.2.1.2 Embolotherapy support devices market, by type
10.5.2.2 By procedure
10.5.2.3 By indication
10.5.2.3.1 Embolotherapy market for cancer, by type
10.5.2.3.2 Embolotherapy market for neurological diseases, by type
10.5.2.4 By end user
Chapter 11. Competitive Landscape
11.1 List of Other Players
11.2 Strategic Developments of Key Players
11.2.1 Product Launches & Approvals
11.2.2 Collaborations
11.2.3 Acquisitions
11.2.4 Expansions
Chapter 12. Company Profiles
12.1 Stryker Corporation
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
12.2 Sirtex Medical Limited
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.2.3 Key Financial Summary
12.3 Merit Medical Systems Inc.
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
12.4 Meril Life Sciences Pvt. Ltd.
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.5 Acandis GmbH
12.5.1 Business Overview
12.5.2 Product and Service Offerings
12.6 Terumo Corporation
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.3 Key Financial Summary
12.7 Medtronic plc
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
12.8 Kaneka Corporation
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
12.9 Johnson & Johnson
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.3 Key Financial Summary
12.10 Boston Scientific Corporation
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
12.11 Abbott Laboratories
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.3 Key Financial Summary
12.12 Guerbet
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.3 Key Financial Summary
12.13 BALT EXTRUSION SAS
12.13.1 Business Overview
12.13.2 Product and Service Offerings
Chapter 13. Appendix
13.1 Abbreviations
13.2 Sources and References
13.3 Related Reports
FIG 59 GUERBET – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2020)"
Note: Product cover images may vary from those shown
  • Stryker Corporation
  • Sirtex Medical Limited
  • Merit Medical Systems Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Acandis GmbH
  • Terumo Corporation
  • Medtronic plc
  • Kaneka Corporation
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Guerbet
  • BALT EXTRUSION SAS
Note: Product cover images may vary from those shown

Loading
LOADING...